GSK-951A, identified by its CAS number 1403602-33-4, is a chemical compound that has garnered attention in pharmaceutical research, particularly in the context of drug development. While specific details about its structure and properties may not be widely available, compounds in this category typically exhibit characteristics such as specific molecular weight, solubility profiles, and potential biological activity. GSK-951A is likely to be evaluated for its efficacy and safety in various biological assays, which may include its interaction with specific biological targets or pathways. As with many compounds in drug discovery, its characteristics would include stability under various conditions, reactivity with other substances, and potential for metabolic transformation in biological systems. The compound's development would also consider its pharmacokinetics and pharmacodynamics, which are crucial for understanding its therapeutic potential. Overall, GSK-951A represents a part of ongoing research efforts aimed at discovering new therapeutic agents.

GSK-951A)

1403602-33-4: GSK-951A, identified by its CAS number 1403602-33-4, is a chemical compound that has garnered attention in pharmaceutical research, particularly in the context of drug development. While specific details about its structure and properties may not be widely available, compounds in this category typically exhibit characteristics such as specific molecular weight, solubility profiles, and potential biological activity. GSK-951A is likely to be evaluated for its efficacy and safety in various biological assays, which may include its interaction with specific biological targets or pathways. As with many compounds in drug discovery, its characteristics would include stability under various conditions, reactivity with other substances, and potential for metabolic transformation in biological systems. The compound's development would also consider its pharmacokinetics and pharmacodynamics, which are crucial for understanding its therapeutic potential. Overall, GSK-951A represents a part of ongoing research efforts aimed at discovering new therapeutic agents.

<p>GSK951A blocks EchA6 and FAS-II, halts mycolic acid formation and MAMES in M. bovis BCG; FAMEs stay mostly unchanged.</p>

CAS 1403602-33-4

GSK-951A)

GSK951A

Ref: TM-T27495